Meta-analysis of <italic style="font-style: italic">Shenqi Jiangtang</italic> Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus

Li Tan; Xingzhong Feng; Huijuan Gao; Ming Tang; Longchao Li; Tingting Li

doi:10.3969/j.issn.2095-6606.2021.05.014

您当前的位置：

首页 >

文章列表页 >

Meta-analysis of Shenqi Jiangtang Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus

更新时间：2021-10-19

- Meta-analysis of Shenqi Jiangtang Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus
- Modern Chinese Clinical Medicine Vol. 28, Issue 5, Pages: 57-64(2021)
- 作者机构：
  
  1.北京中医药大学东直门医院　北京　 100700
  2.清华大学玉泉医院
  3.首都医科大学附属北京世纪坛医院
  4.北京中医药大学
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.2095-6606.2021.05.014
  CLC： R255.4
- Published：30 September 2021，
  
  Received：04 September 2020，
- 稿件说明：
移动端阅览
Li Tan, Xingzhong Feng, Huijuan Gao, et al. Meta-analysis of Shenqi Jiangtang Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus. [J]. Modern Chinese Clinical Medicine 28(5):57-64(2021)
DOI：

Li Tan, Xingzhong Feng, Huijuan Gao, et al. Meta-analysis of Shenqi Jiangtang Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus. [J]. Modern Chinese Clinical Medicine 28(5):57-64(2021) DOI： 10.3969/j.issn.2095-6606.2021.05.014.

摘要

目的

系统评价参芪降糖剂联合二肽基肽酶IV(dipeptidy l peptidase 4，DPP-4)抑制剂治疗2型糖尿病有效性和安全性。

方法

计算机检索中国知网(CNKI)、中文科技期刊数据库(VIP)、中国生物医学文献数据库(CBM)、万方数据库(Wan Fang)，PubMed，Embase，Cochrane Library等数据库，收集参芪降糖剂联合DPP-4抑制剂治疗2型糖尿病的随机对照试验研究(randomized controlled trial，RCT)。由2名研究者根据纳入排除标准、Cochrane偏倚风险评估工具独立进行文献筛选、方法学质量评价，采用RevMan 5.3软件对纳入研究进行数据分析。

结果

共纳入8个RCT研究，共843例患者，其中治疗组422例患者，对照组421例患者。治疗组总有效率优于对照组(RR＝1.19，95%CI[1.09，1.30]，

0.000 1)；治疗组降低空腹血糖疗效优于对照组(

＝-1.62，95%CI[-1.80，-1.44]，

0.000 01)；治疗组降低餐后2 h血糖的疗效优于对照组(WMD＝-1.01，95%CI[-1.15，-0.86]，

0.000 01)；治疗组降低HbA1c的疗效优于DPP-4抑制剂组，差异有统计学意义(

＝-1.23，95%CI[-1.41，-1.04]，

0.000 01)；治疗组胰岛素抵抗指数降低优于对照组(

＝-0.79，95%CI[-0.87，-0.71]，

0.000 01)；治疗组胰岛β细胞功能指数改善优于对照组(

＝12.45，95%CI[11.31，13.59]，

0.000 01)；治疗组IL-6下降程度优于对照组(

＝-9.60，95%CI[-10.21，-9.00]，

0.000 01)；治疗组不良反应发生率明显低于对照组(RR＝0.32，95%CI[0.17，0.58]，

＝0.000 2

0.05)。

结论

参芪降糖剂联合DPP-4抑制剂治疗2型糖尿病疗效优于DPP-4抑制剂组，不良反应发生率明显低于DPP-4抑制剂组。后期需更多高质量、大样本、多中心RCT，验证参芪降糖剂联合DPP-4抑制剂治疗2型糖尿病的临床疗效和安全性。

Abstract

Objective

To systemically evaluate the validity and safety of

Shenqi Jiangtang

Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus.

Methods

Randomized controlled trials (RCT) of

Shenqi Jiangtang

Agent combined with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus were collected from China National Knowledge Infrastructure(CNKI)

Chinese Science and Technology Journal Database (VIP)

China Biomedical Literature Database (CBM)

Wan Fang Database (Wan Fang)

PubMed

Embase

Cochrane Library and other databases. According to the inclusion and exclusion criteria and the Cochrane bias risk assessment tool

two researchers independently conducted literature screening and methodological quality evaluation. RevMan 5.3 software was used to analyze the data of the included studies.

Results

A total of 8 RCT studies were included with a total of 843 patients

including 422 patients in the

Shenqi Jiangtang

Agent combined with DPP-4 inhibitors group(treatment group) and 421 patients in the DPP-4 inhibitors group(control group). The total effective rate was better in the treatment group than in the control group (RR=1.19

95%CI[1.09

1.30]

0.000 1); the treatment group had a better efficacy in reducing fasting blood glucose than the control group (

=-1.62

95%CI[-1.80

-1.44]

0.000 01); the effect of reducing blood glucose 2 hours after a meal was better in the treatment group than in the control group (WMD=-1.01

95%CI[-1.15

-0.86]

0.000 01); the efficacy of HbA1c was more significantly reduced in the treatment group than in the control group (

=-1.23

95%CI[-1.41

-1.04]

0.000 01); the treatment group had better insulin resistance index reduction than the control group (

=-0.79

95% CI[-0.87

-0.71]

0.000 01). The improvement of pancreatic β-cell function index was better in the treatment group than in the control group (

=12.45

95% CI[11.31

13.59]

0.000 01). The decrease of IL-6 was better in the treatment group than in the control group (

=-9.60

95%CI[-10.21

-9.00]

0.000 01). The incidence of adverse reactions was significantly lower in the treatment group than in the control group (RR=0.32

95%CI[0.17

0.58]

=0.000 2

0.05).

Conclusions

Shenqi Jiangtang

Agent combined with DPP-4 inhibitors has a better therapeutic efficacy for type 2 diabetes mellitus than DPP-4 inhibitors

with a remarkably lower incidence of adverse reactions in the

Shenqi Jiangtang

Agent combined with DPP-4 inhibitors group than in the DPP-4 inhibitors group. More high-quality

large-scale samples

multi-center RCTs are needed in the future to verify the clinical efficacy and safety of

Shenqi Jiangtang

Agent combined with DPP-4 inhibitors in the treatment of for type 2 diabetes mellitus.

关键词

参芪降糖剂二肽基肽酶IV抑制剂2型糖尿病随机对照试验Meta分析

Keywords

Shenqi Jiangtang Agentdipeptidy l peptidase 4 inhibitortype 2 diabetes mellitusrandomized controlled trialmeta-analysis

references

王辰，王建安. 内科学：下册[M].3版.北京：人民卫生出版社，2015：1074-1075.

SAEEDI P，PETERSOHN I，SALPEA P，et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition[J/OL].Diabetes Res Clin Pract，2019,157:107843[2020-09-01].https://doi.org/10.1016/j.diabres.2019.107843https://doi.org/10.1016/j.diabres.2019.107843.

王瑶，于燕婷，黄国伟，等.维生素D与2型糖尿病发病的关系及机制研究进展[J].中国慢性病预防与控制，2019,27(6):462-464.

周文娟，吴云翔，易军.糖化血红蛋白标准化及其检测技术的发展[J].生物化学与生物物理进展，2015,42(5):443-456.

中华医学会内分泌学会. 中国成人2型糖尿病口服降糖药联合治疗专家共识[J].中华内分泌代谢杂志，2019,35(3):190-199.

ZHANG Q，XIAO X，LI M，et al.Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats[J/OL].PLoS One，2017,12(10):e0184735[2020-09-02].https://journals.plos.org/plosone/article？id＝10.1371/journal.pone.0184735https://journals.plos.org/plosone/article？id＝10.1371/journal.pone.0184735.

KUSUNOKIM，SATO D，NAKAMURA T，etal.The beneficial effects of the DPP-4 inhibitor Alogliptin on hemoglobin A1c and serum lipids in Japanese patients with type 2 diabetes[J].Drug Res，2015,66(1):18-22.

杨璐瑶，胡琼英.中药治疗2型糖尿病的研究进展[J].中国中西医结合杂志，2020,40(8):1007-1011.

NIE Q，CHEN H，HU J，et al.Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota[J].Critical Reviews in Food Science and Nutrition，2018,59(6):848-863.

张晶，李冰冰，黄敏仪，等.基于网络药理学的参芪降糖剂治疗2型糖尿病机制探讨[J].中草药，2020,51(19):4873-4883.

路俊华.参芪降糖颗粒联合盐酸二甲双胍治疗2型糖尿病疗效分析[J].中国药业，2017,26(24):50-52.

李红典，李明轩，白薇，等.参芪降糖颗粒联合二甲双胍治疗2型糖尿病有效性及安全性的Meta分析[J].世界中西医结合杂志，2020,15(9):1630-1637.

HIGGINS J, GREEN S. Cochrane handbook for systematic reviews of interventions(Version 5.1.0.)[EB/OL].[2011-03-01](2020-06-09).http://handbook-5-1.coc-hrane.org/http://handbook-5-1.coc-hrane.org/.

范艺龄，苗青，廖星，等.六君子汤联合西医疗法治疗慢性阻塞性肺疾病稳定期的有效性和安全性随机对照试验的系统评价和Meta分析[J].中国中药杂志，2020,45(22):5331-5343.

王庆宇.二肽基肽酶Ⅳ抑制剂联合参芪降糖颗粒治疗2型糖尿病患者临床效果观察[J].实用糖尿病杂志，2020,16(3):7.

高飞龙.二肽基肽酶抑制剂联合参芪降糖颗粒治疗2型糖尿病患者临床效果观察[J].首都食品与医药，2020,27(8):75.

张艳召.参芪降糖颗粒联合西格列汀二甲双胍片治疗2型糖尿病患者[J].实用中西医结合临床，2019,19(4):19-21.

王萍.两种药物联合对2型糖尿病血糖控制及生活质量的影响[J].深圳中西医结合杂志，2019,29(4):145-146.

任启伟.沙格列汀联合参芪降糖颗粒治疗2型糖尿病46例临床观察[J].中国民族民间医药，2019,28(2):105-106,120.

安淑选.二肽基肽酶-4抑制剂联合参芪降糖颗粒治疗2型糖尿病的效果[J].河南医学研究，2018,27(24):4491-4492.

程灿，陈传绮，鄢燕琼，等.参芪降糖颗粒联合磷酸西格列汀片治疗2型糖尿病伴代谢综合征77例疗效观察[J].中国药业，2018,27(23):44-46.

刘艳菊.二肽基肽酶-4抑制剂联合参芪降糖颗粒对2型糖尿病患者FPG、2hPG水平变化的影响[J].北方药学，2018,15(10):119-120.

史雅琼，马建伟.2型糖尿病患者中医证型分布及其并发症证型特点[J].河南中医，2017,37(10):1789-1791.

赵进喜，冯兴中，仝小林，等.论糖尿病的中医核心病机与基本治法[J].北京中医药，2019,38(1):3-6.

佘卫吉，刘继彰，巩慧.参芪降糖颗粒治疗2型糖尿病的临床研究[J].世界中医药，2019,14(12):3294-3297.

苟卓越，王天晟，马满玲，等.GLP-1受体激动剂和DPP-4抑制剂胃肠道不良反应的系统评价和Meta分析[J].中国药学杂志，2014,49(11):935-940.

徐风，杨东辉，尚明英，等.中药药效物质的“显效形式”、“叠加作用”和“毒性分散效应”——由中药体内代谢研究引发的思考[J].世界科学技术-中医药现代化，2014,16(4):688-703.

赵能江，杨叔禹，李博.参芪降糖颗粒治疗2型糖尿病临床应用专家共识[J].中草药，2020,51(17):4383-4387.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

针刺辅助治疗糖尿病肾脏病的Meta分析

Literature study on outcome indexes of randomized controlled trials of traditional Chinese medicine therapy in children with ADHD

Clinical characteristics and syndrome regularity of patients with type 2 diabetes mellitus complicated with cerebral small vessel disease

Systematic review and meta-analysis on the relationship between asthma and TCM constitution^*

基于医院与社区比较的中医非药物疗法治疗原发性高血压随机对照试验的现状与特征分析

Related Author

姚志

陈美玲

金化男

张笑笑

郑启艳

孙鲁英

赵庆

WANG Zi

Related Institution

Dongzhimen Hospital, Beijing University of Cohinese Medicine

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Liaoning University of Traditional Chinese Medicine

Beijing Nuclear Industry Hospital

⁰

Meta-analysis of Shenqi Jiangtang Agent combined with dipeptidy l peptidase 4 inhibitors for type 2 diabetes mellitus

DOI：10.3969/j.issn.2095-6606.2021.05.014

摘要

Abstract

关键词

Keywords

references